An equal number of patients was selected for each disease (n=3), Fig. S1A -B. The samples were prepared according to the ST protocol as previously described (Fig. S1  C) . 24 
Method optimization for RA and SpA tissue for Spatial Transcriptomics
The optimal conditions for tissue permeabilization and tissue removal for the Spatial Transcriptomics protocol were determined. This process uses cDNA synthesis with Cy3-labeled dCTPs to create a fluorescent footprint of cDNA, as previously described. 1 For RA and SpA tissues, the following parameters were selected: The tissue biopsies were sectioned at 7μm, fixed in 2% NBF (neutral buffered formalin) for 10min and stained with Hematoxylin for 7min. The prepermeabilization step was performed with a 20min incubation at 37°C in 14U of collagenase type I (Life Technologies, Paisley, UK) diluted in 1xHBSS buffer (Thermo Fisher Scientific, Life Technologies, Paisley, UK) supplemented with 1% BSA (NEB, Ipswich, MA, USA). For permeabilization, the sections were incubated in 0.1% pepsin-HCl (pH 1) for 8min at 37°C. For the tissue removal, the tissue was first incubated for 1h at 56°C in beta-mercaptoethanol which was diluted in RLT buffer (x4). After that, the tissue was treated with proteinase K diluted in PKD buffer at a ratio of 1:7 for 1h at 56°C, as previously described. The cDNA footprint was revealed by scanning the slide in an InnoScan 910 Microarray Scanner with 5μm resolution and gain at 10% or with a Metafer VSlide system at 20x resolution. An image showing the cDNA-footprint from one of the tissue optimizations can be seen in Fig. S2A -C. Figure S1 . Overview of the patient samples and the spatial transcriptomics assay (A) Depiction of the joint biopsies (knee and hip) and brief patient characteristics. (B) Age, gender and disease duration at the timepoint of collection. Treatments at time of sampling include 1; DMARDs, 2; TNF inhibitors, 3; anti-IL-6R blockers, 4; glucocorticoids. (C) Depiction of the main steps of the spatial transcriptomics method starting with cryosectioning (three sections per biopsy), cDNA synthesis, tissue removal and release on surface cDNA, library preparation, DNA-sequencing and analysis.
Supplementary figures

Figure S2. Spatial Transcriptomics optimization assay (A)
An overview of the cDNA synthesis step for the ST optimization assay. The surface probes are distributed all over the surface area, and cDNA synthesis is conducted with Cy3-labeled dCTPs in the nucleotide mixture and thereafter scanned with a 532 nm light source. (B) Shows the same section scanned with the Metafer VSlide system (H&E image to the left) and scanned on 532 nm after the tissue section was removed (to the right). The cDNA footprint can be seen with no signal diffusion and also less signal in areas with less cells (shown with an arrow). The small white circles 1-4 is areas in which the signal intensity was measured seen in (C) which shows the average signal intensities measured with GenePix Pro 5.0 from the circular areas with error bars.
Figure S3. Cluster selection for RA-A 3
Black lines are regions annotated as lymphocyte infiltrates. Each spot represent areas in which mRNA was captured from. The numbers and colours represent the different clusters that were assigned. For the bulk analysis all spots were selected. For the infiltrate analysis cluster 4 was selected. For the outside-infiltrate analysis clusters 1 and 3 were selected.
Figure S4. Larger set of genes from the DE analysis on the bulk data.
The dendrograms were ordered so that all RA-samples are to the left and all SpAsamples to the right. For each selection, all genes that had a log2fold change >2 and p-value lower than 0.01 from the DE-analysis are shown. N.B. the reference genome GRCh38 only maps to the haplotype HLA-DR1, which contains HLA-DRB1 and HLA-DRB5 which is a homolog of HLA-DRB4. It is possible that faulty mapping can occur for specific variable genes like the ones building the MHC structures. The genes known to have this issue have been marked with *.
Figure S5. Larger set of genes from the DE analysis of selected clusters correlating to infiltrate regions.
The dendrograms were ordered so that all RA-samples are to the left and all SpAsamples to the right. For each selection, all genes that had a log2fold change >2 and p-value lower than 0.01 from the DE-analysis are shown.N.B. the reference genome GRCh38 only maps to the haplotype HLA-DR1, which contains HLA-DRB1 and HLA-DRB5 which is a homolog of HLA-DRB4. It is possible that faulty mapping can occur for specific variable genes like the ones building the MHC structures. The genes known to have this issue have been marked with *.
Figure S6. Larger set of genes from the DE analysis of selected clusters correlating to regions outside the infiltrates.
The dendrograms were ordered so that all RA-samples are to the left and all SpAsamples to the right. For each selection, all genes that had a log2fold change >2 and p-value lower than 0.01 from the DE-analysis are shown. N.B. the reference genome GRCh38 only maps to the haplotype HLA-DR1, which contains HLA-DRB1 and HLA-DRB5 which is a homolog of HLA-DRB4. It is possible that faulty mapping can occur for specific variable genes like the ones building the MHC structures. The genes known to have this issue have been marked with *. Table S1 . Top canonical pathways from IPA on bulk data. In the tables, similarities are marked in blue.
Supplementary tables
RA (overlap %) SPA (overlap %)
Primary Immunodeficiency signaling (20.5%) Tumoricidal function of hepatic natural killer cells (12.5%) Th1 pathway (11.6%) Th1 and Th2 activation pathway (3.4%) iCOS-iCOSL signaling in T helper cells (11.9%) Th1 pathway (3.9%) Regulation of IL-2 expression in activated and anergic T lymphocytes (13.9%) 
